Navigation Links
Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting
Date:11/6/2009

HAYWARD, Calif., Nov. 6 /PRNewswire/ -- Intarcia Therapeutics, Inc. delivered two presentations today on its ITCA 650 (DUROS® continuous delivery of exenatide) program for the treatment of type 2 diabetes at the Ninth Annual Diabetes Technology Meeting in San Francisco, CA:

(Logo: http://www.newscom.com/cgi-bin/prnh/20050301/SFTU126LOGO)

Continuous Subcutaneous Delivery of Exenatide Via ITCA 650 Lowers Plasma Glucose, HbA1c and Reduces Weight in a 28-day Phase 1b Study in Type 2 Diabetes, K. Luskey, J. McNally, J. Dahms, T. Alessi

Stability of ITCA 650 for Continuous Subcutaneous Delivery of Exenatide at Body Temperature for 12 Months, B. Yang, C. Negulescu, R. D'Vaz, C. Eftimie, J. Carr, S. Lautenbach, K. Horwege, R. Mercer, D. Ford, T. Alessi

Intarcia's ITCA 650 phase 1b clinical study was conducted at multiple centers in the United States and evaluated a 28-day course of ITCA 650 treatment among in patients with type 2 diabetes on a stable treatment regimen of diet and exercise or treatment with metformin and/or thiazolidinediones. The study included 4 dose arms (10-12 patients/dose arm) to which patients were randomized to receive 10 mcg/day, 20mcg/day, 40 mcg/day or 80 mcg/day of exenatide for a 28-day treatment duration. ITCA 650 therapy was administered for the full course of treatment with a single insertion of the ITCA 650 on day 1 and removal on day 29.

    Fasting & Postprandial Glucose  ITCA 650 Dose Arms (continuous daily dose)
                                    -----------------------------------------
                                      10          20          40         80
                                    mcg/day     mcg/day     mcg/day    mcg/day
                                 
'/>"/>
SOURCE  Intarcia Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 

Related biology technology :

1. Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference
2. Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes
3. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
4. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
5. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
6. Cell Therapeutics, Inc.s (CTI) Presentation at BIO Investor Forum to be Webcast
7. Oxygen Biotherapeutics, Inc. Expands Board of Directors
8. The Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.
9. New Oxygen Biotherapeutics, Inc. Investor Presentation Available on Company Website
10. Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report
11. Sorrento Therapeutics, Inc. and QuikByte Software, Inc. Complete Merger
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... May 24, 2013 Dr. Ingrid Warmuth and ... Swedesboro, NJ, are proud to announce an Open House at ... place on Saturday, June 8th from 10 AM to 2 ... Newport, MHS, PA-C and staff will be on hand to ... and aesthetic treatments, and provide complimentary cosmetic consultations. There will ...
(Date:5/24/2013)... WA (PRWEB) May 24, 2013 ... engineers, and industry suppliers will present technologies with ... at the annual SPIE Optics and Photonics ... Organized by SPIE, the international society for ... largest international, multidisciplinary optical sciences and technology meeting ...
(Date:5/24/2013)... Bed bug cases tend to increase during summer. And ... risk of becoming the pests' next victim throughout the season, ... the guide, the company enumerated the steps of getting ... , According to My Cleaning Products, there are two ... during summer: the warm weather and the rise in travel. ...
(Date:5/24/2013)... BOSTON and TEL AVIV, Israel ... ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in ... , the Company,s President and Chief Executive Officer, and ... will participate in the Benchmark Company, LLC One-on-One Investor Conference ... East Wisconsin Ave., Milwaukee, WI. ...
Breaking Biology Technology:See What’s in Earth’s Future ? and Out in Space Now ? at SPIE Optics and Photonics 2See What’s in Earth’s Future ? and Out in Space Now ? at SPIE Optics and Photonics 3See What’s in Earth’s Future ? and Out in Space Now ? at SPIE Optics and Photonics 4Steps for Getting Rid of Bed Bugs without Using Chemicals and Avoiding Them While Traveling Enumerated by My Cleaning Products in Its Latest Post 2Steps for Getting Rid of Bed Bugs without Using Chemicals and Avoiding Them While Traveling Enumerated by My Cleaning Products in Its Latest Post 3InspireMD To Participate In Benchmark Investor Conference On May 30th 2InspireMD To Participate In Benchmark Investor Conference On May 30th 3InspireMD To Participate In Benchmark Investor Conference On May 30th 4
... DIEGO, March 16 Prometheus Laboratories Inc., a specialty ... received New York State approval for PROMETHEUS(R) IBS Diagnostic, ... syndrome (IBS). This novel test incorporates 10 biomarkers, ... algorithm to help physicians diagnose patients with IBS."One out ...
... N.J., March 16 DOR BioPharma, Inc. (OTC Bulletin ... it has appointed Gregg Lapointe, CPA, MBA, to its ... Executive Officer of Sigma-Tau Pharmaceuticals, Inc. (Sigma-Tau), a company ... patients with rare diseases. Sigma-Tau is DOR,s North American ...
... experts will address the benefits of rigorous early phase ... American Society for Clinical Pharmacology and Therapeutics (ASCPT), to ... Harbor, Maryland from March 18 - 21, 2009. The ... be to help biopharmaceutical companies understand best practice approaches ...
Cached Biology Technology:Prometheus Receives New York State Approval for PROMETHEUS(R) IBS Diagnostic, First Blood Test for Irritable Bowel Syndrome 2DOR BioPharma Appoints Gregg Lapointe, CPA, MBA, to its Board of Directors 2DOR BioPharma Appoints Gregg Lapointe, CPA, MBA, to its Board of Directors 3DOR BioPharma Appoints Gregg Lapointe, CPA, MBA, to its Board of Directors 4PAREXEL Experts to Address Benefits of Rigorous Early Phase Development at Annual ASCPT Meeting 2PAREXEL Experts to Address Benefits of Rigorous Early Phase Development at Annual ASCPT Meeting 3PAREXEL Experts to Address Benefits of Rigorous Early Phase Development at Annual ASCPT Meeting 4
(Date:5/23/2013)... RICHLAND, Wash. Pacific Northwest National Laboratory honored ... and commercialization of intellectual property at PNNL,s annual ... , The Department of Energy national laboratory ... Year for his work developing battery materials that ... to the electrical grid, and reduce the time ...
(Date:5/23/2013)... Investigators at Rollins School of Public Health at ... Institute of Technology, have received a $4 million ... Center at Emory University (Health and Exposome Research ... first exposome-based center grant awarded in the United ... by the National Institute of Environmental Health Sciences ...
(Date:5/23/2013)... DNA around nucleosomes in the cell nucleus makes ... Ludwig-Maximilians-Universitaet (LMU) in Munich now describes a mechanism ... from nucleosomes for transcription. , In higher organisms ... nucleus, wrapped around disk-shaped particles called nucleosomes, each ... proteins and accommodating two loops of DNA. Packed ...
Breaking Biology News(10 mins):PNNL staff recognized for scientific accomplishments, moving technologies into the marketplace 2Emory, Georgia Tech receive first human exposome center grant in US 2Emory, Georgia Tech receive first human exposome center grant in US 3Biochemistry: Unspooling DNA from nucleosomal disks 2
... the Greek island. Damage is widespread and all conventional, ... only one means at their disposal that has not ... from its altitude of 36 000 kilometres, can immediately ... appropriate authorities. Thankfully, this was only a two-day ...
... A noninvasive, polarized light microscope invented at the Marine ... recent breakthrough in embryonic stem-cell research aimed at developing ... Ph.D., of Oregon Health & Science University reported ... embryos in the November 22 issue of Nature. While ...
... brain injury and using club drugs have in common" ... chemical chain reaction in the brain, leading to cell death, ... series of studies at UF over the past five years ... MDMA, and other forms of methamphetamine lead to the same ...
Cached Biology News:Telemedicine: Health alert via satellite 2Oosight microscope enables embryonic stem cell breakthrough 2Oosight microscope enables embryonic stem cell breakthrough 3Oosight microscope enables embryonic stem cell breakthrough 4Club drugs inflict damage similar to traumatic brain injury 2Club drugs inflict damage similar to traumatic brain injury 3
S-100A10 (H-80)...
... Shimadzu Biotech presents PsiPort Mass ... data review and data acquisition system ... purification for the life science and ... been designed specifically to simplify high ...
SP6 RNA Polymerase, 50 l, 20 U/l ,Cap Scribe Buffer, 100 l, 5x conc....
... T4 Polynucleotide Kinase catalyzes the ... ATP to the 5-terminus of ... a 5-hydroxyl group. The enzyme, ... may be used to phosphorylate ...
Biology Products: